July 1, 2021
July 1, 2021 | Insilico Medicine closes a Series C for AI-powered drug discovery, while other investments fuel remote access labs, natural products, high throughput screening, and more.
$550M: VC Fund for Therapeutics for Unmet Needs
venBio has announced the closing of venBio Global Strategic Fund IV, LP (“venBio Fund IV”), its fourth life sciences venture capital fund, exceeding its target and closing on approximately $550 million in capital commitments in an oversubscribed fundraise. The capital was raised from existing and new investors, including a broad range of institutional investors comprising corporate pensions, financial institutions, university endowments and foundations, family offices and funds-of-funds. Led by Managing Partners Corey Goodman, Ph.D., Robert Adelman, M.D., Aaron Royston, M.D., and Richard Gaster, M.D., Ph.D., venBio Fund IV will continue to invest primarily in therapeutics companies that are developing biopharmaceuticals
venBio Writes New Chapter with $550M Fourth Fund genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
venBio Raises $550 Million Venture Capital Fund Focused on Life Sciences - read this article along with other careers information, tips and advice on BioSpace
venBio Closes Venture Capital Fund Focused on Life Sciences, At $550M
venBio, a Palo Alto, CA and San Francisco, CA-based closed its fourth life sciences venture capital fund, venBio Global Strategic Fund IV, LP, at approximately $550m.
The capital was raised from existing and new investors, including a broad range of institutional investors comprising corporate pensions, financial institutions, university endowments and foundations, family offices and funds-of-funds.
Led by Managing Partners Corey Goodman, Ph.D., Robert Adelman, M.D., Aaron Royston, M.D., and Richard Gaster, M.D., Ph.D., venBio Fund IV will continue to invest primarily in therapeutics companies that are developing biopharmaceuticals for unmet medical needs. The venBio team takes an active role with each of their portfolio companies, providing strategic guidance on a range of business activities including intellectual property, chemistry, manufacturing and controls (CMC), as well as assisting with clinical trials
MedCity News
Read about new developments from Stellar Health, Paige, venBio, and more.
Shares0
Stellar Health is pleased to announce the appointment of JoRel Nye, former Senior Vice President of Technical Product Management at Aledade as its new Chief Product Officer.
Stellar Health is a point-of-care, cloud-based platform that helps primary care providers continually engage with their patients by providing them real-time information and tangible action-based incentives for improving quality of care. Stellar Health’s mission is to enable all providers to engage and succeed in VBC by bridging the incentive gap between providers and payors. To read more,
Paige co-founder Dr. David Klimstra has been named Chief Medical Officer, a role that will start in August. Klimstra is currently Chair of the Department of Pathology at Memorial Sloan Kettering Cancer Center. In his new role, Klimstra will lead the clinical implementation and evidence generation for Paige’s technology and